$1.75
0.021.16%
In chiusura: -
$1.74
-0.00950-0.54%
After hour: 4:50 PM EDT
Lineage Cell Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Lineage Cell Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
LCTX | Lineage Cell Therapeutics | -$0.02 | -$0.02 | — | — | $3.78M | $2.43M | — | — | 11/13/2025 | |
LCTX | Lineage Cell Therapeutics | -$0.03 | -$0.02 | -$0.07 | -250.00% | $1.41M | $1.52M | $2.77M | 82.44% | 08/12/2025 | |
LCTX | Lineage Cell Therapeutics | -$0.04 | -$0.03 | -$0.02 | 33.33% | $1.44M | $1.72M | $1.50M | -12.67% | 05/13/2025 | |
LCTX | Lineage Cell Therapeutics | -$0.03 | -$0.03 | -$0.02 | 33.33% | $2.10M | $1.62M | $2.90M | 79.01% | 03/10/2025 | |
LCTX | Lineage Cell Therapeutics | -$0.04 | -$0.03 | -$0.02 | 33.33% | $1.25M | $886.57K | $3.78M | 326.25% | 11/14/2024 | |
LCTX | Lineage Cell Therapeutics | -$0.03 | -$0.04 | -$0.03 | 25.00% | $3.23M | $970.00K | $1.41M | 45.15% | 08/08/2024 | |
LCTX | Lineage Cell Therapeutics | -$0.03 | -$0.04 | -$0.04 | 0.00% | $2.39M | $1.36M | $1.44M | 6.18% | 05/09/2024 | |
LCTX | Lineage Cell Therapeutics | -$0.03 | -$0.04 | -$0.03 | 25.00% | $1.90M | $1.31M | $2.10M | 60.31% | 03/07/2024 | |
LCTX | Lineage Cell Therapeutics | -$0.04 | -$0.04 | -$0.04 | 0.00% | $3.00M | $2.59M | $1.25M | -51.89% | 11/09/2023 | |
LCTX | Lineage Cell Therapeutics | -$0.04 | -$0.04 | -$0.03 | 25.00% | $4.55M | $2.20M | $3.23M | 46.59% | 08/10/2023 | |
LCTX | Lineage Cell Therapeutics | -$0.04 | -$0.04 | -$0.03 | 25.00% | $5.24M | $2.01M | $2.39M | 18.71% | 05/11/2023 | |
LCTX | Lineage Cell Therapeutics | -$0.17 | -$0.04 | -$0.03 | 25.00% | $1.20M | $2.57M | $1.90M | -26.07% | 03/09/2023 | |
LCTX | Lineage Cell Therapeutics | -$0.05 | -$0.03 | -$0.04 | -33.33% | $2.27M | $3.90M | $3.00M | -23.13% | 11/10/2022 | |
LCTX | Lineage Cell Therapeutics | -$0.03 | -$0.04 | -$0.04 | 0.00% | $512.00K | $3.68M | $4.55M | 23.72% | 08/11/2022 | |
LCTX | Lineage Cell Therapeutics | -$0.01 | -$0.03 | -$0.04 | -33.33% | $391.00K | $7.32M | $5.24M | -28.46% | 05/12/2022 | |
LCTX | Lineage Cell Therapeutics | $0.01 | -$0.05 | -$0.17 | -240.00% | $355.00K | $840.00K | $1.20M | 42.86% | 03/10/2022 | |
LCTX | Lineage Cell Therapeutics | -$0.05 | -$0.05 | -$0.05 | 0.00% | $571.00K | — | $2.27M | — | 11/10/2021 | |
LCTX | Lineage Cell Therapeutics | -$0.04 | -$0.04 | -$0.03 | 25.00% | $386.00K | $480.00K | $512.00K | 6.67% | 08/12/2021 | |
LCTX | Lineage Cell Therapeutics | -$0.06 | -$0.04 | -$0.01 | 75.00% | $514.00K | $790.00K | $391.00K | -50.51% | 05/13/2021 | |
LCTX | Lineage Cell Therapeutics | -$0.03 | -$0.05 | $0.01 | 120.00% | $1.24M | $920.00K | $355.00K | -61.41% | 03/11/2021 | |
LCTX | Lineage Cell Therapeutics | -$0.11 | -$0.04 | -$0.05 | -25.00% | $567.00K | $430.00K | $571.00K | 32.79% | 11/04/2020 |
Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-12 | $-0.07 | $-0.02 | -250.0 % |
Q1 | 2025-05-13 | $-0.02 | $-0.03 | 33.3 % |
Q4 | 2025-03-10 | $-0.02 | $-0.03 | 33.3 % |
Q3 | 2024-11-14 | $-0.02 | $-0.03 | 33.3 % |
Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-12 | $2.77M | $1.52M | 82.4 % |
Q1 | 2025-05-13 | $1.50M | $1.72M | -12.7 % |
Q4 | 2025-03-10 | $2.90M | $1.62M | 79.0 % |
Q3 | 2024-11-14 | $3.78M | $886.57K | 326.3 % |
Si prevede che Lineage Cell Therapeutics (LCTX) fornisca risultati il novembre 13, 2025. Gli ultimi risultati sono stati pubblicati il agosto 12, 2025 per il Q2.
L'EPS effettivo era $-0.07, che mancato la stima di $-0.02.
Le entrate effettive sono state $2.8M, che superato la stima di $1.5M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.